ADC Therapeutics Projects Strong 2025 Revenue and Future Growth
ADC Therapeutics SA (NYSE: ADCT), a recognized innovator in antibody drug conjugates (ADCs), has disclosed preliminary estimates indicative of approximately $22 million in net product revenue for the fourth quarter and around $73 million for the entire year of 2025. This strong financial performance is bolstered by a robust cash reserve of about $261 million, which is projected to sustain operations well into 2028. These financial standings set a promising stage for future growth and development in the business.
Exciting near-term catalysts are on the horizon for the company. ADC Therapeutics expects to complete enrollment for its LOTIS-7 clinical trial in the first half of 2026. Additionally, pivotal topline data from the LOTIS-5 Phase 3 study is anticipated in the second quarter of 2026. These developments are critical for the company's growth trajectory and for advancing their innovative therapies in oncology.
CEO Ameet Mallik expressed confidence in the company's direction, stating significant strides were made in the ZYNLONTA clinical program throughout 2025. With further results expected from the LOTIS-5 and LOTIS-7 trials, along with potential inclusion in treatment compendia in the first half of 2027, the future looks bright for ADC Therapeutics. The positive outcomes from these studies could lead to increased product revenue growth starting in 2027.
Recent Highlights and Financial Developments
Predictions for the 2025 financial results signal exciting advancements. The projected $73 million in net product revenue for 2025 represents a slight increase from the $69.3 million recorded in 2024. The expected revenue from the fourth quarter showcases a substantial rise compared to the previous year, reinforcing underlying demand for ZYNLONTA remains stable in the treatment for diffuse large B-cell lymphoma (DLBCL).
The company also reported updated data from the LOTIS-7 trial, which demonstrated impressive efficacy with a best overall response rate of 89.8% and complete response rate of 77.6% across evaluable patients. Full data is expected to be shared through publication by late 2026, and ongoing enrollment of around 100 patients is anticipated to be completed soon.
LOTIS-5 Trial and Future Developments
Later this year, ADC Therapeutics is set to present topline data from the LOTIS-5 Phase 3 trial, investigating ZYNLONTA in combination with rituximab. Following the achievement of pre-specified endpoints, the publication of complete results is expected by the end of 2026. If results are favorable, plans will proceed for a supplemental Biologics License Application submission to the FDA, alongside anticipated peer-reviewed publication.
In parallel, the company has embarked on investigator-initiated trials focused on indolent lymphomas, presenting promising findings from the Phase 2 clinical trials targeting both follicular lymphoma and marginal zone lymphoma. These findings could pave the way for advancements in regulatory strategies contingent upon positive data outcomes by late 2026.
Innovative Product Development
ADC Therapeutics is also making significant progress in developing its prostate-specific membrane antigen (PSMA)-targeting ADC. With IND-enabling activities now complete, the company is actively exploring partnership opportunities to expedite the process of bringing this innovative treatment to market.
About ADC Therapeutics
ADC Therapeutics is revolutionizing the treatment landscape for cancer through its focused approach to ADC development. Its flagship product ZYNLONTA has received accelerated regulatory designations by the FDA and European Commission for treating patients facing relapsed or refractory DLBCL, following multiple treatments. With headquarters in Lausanne, Switzerland, ADC Therapeutics is dedicated to ongoing research and the commercial realization of its innovative therapies.
Frequently Asked Questions
What is ADC Therapeutics' projected revenue for 2025?
ADC Therapeutics projects approximately $73 million in net product revenue for the year 2025.
When will key results from LOTIS-5 be available?
Topline results from the LOTIS-5 Phase 3 trial are anticipated in the second quarter of 2026, with full results expected by the end of that year.
What financial position does ADC Therapeutics hold?
The company reports cash reserves of around $261 million, providing a runway for operation at least until 2028.
What are the key expected clinical milestones for ADC Therapeutics?
Important milestones include the completion of LOTIS-7 enrollment and data from the LOTIS-5 trial, which are critical to the company's growth.
Where is ADC Therapeutics headquartered?
ADC Therapeutics is headquartered in Lausanne, Switzerland, with additional operational locations in London and New Jersey.
